Salvina Therapeutics has unlocked a novel approach for selectively targeting TNF and other TNF superfamily members, resulting in the generation of antibodies with a highly innovative mode of action. These have the potential to significantly improve the benefit/risk ratio of TNF targeting in certain diseases and enable bispecific therapies that have not been developable to date.
Company Details
- Employees
- 4
- Address
- C/o Switzerland Innovation Park Basel Area, Hegenheimermattweg 167a,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Allschwil
Salvina Therapeutics Questions
Salvina Therapeutics's LinkedIn profile is https://ch.linkedin.com/company/salvina-therapeutics
Salvina Therapeutics has
4 employees.
View email and phone details for 4
employees at Salvina Therapeutics.
Salvina Therapeutics's industry is
Biotechnology Research
Salvina Therapeutics's top competitors are
Mabylon Ag,
Phialogics - The Native Biologics Platform Company,
Tandem Therapeutics,
Nxi Therapeutics Ag,
Pharmabiome Ag,
Engimmune Therapeutics,
Aukera Therapeutics,
Onena Medicines,
Alentis Therapeutics,
Inositec Ag.
Salvina Therapeutics's categories are Biotechnology Research
